Gengos Andrew purchased $90K of IMRX

Gengos Andrew (Chief Financial Officer) purchased 25,000 shares of Immuneering Corp (IMRX) at $3.58 on 2026-11-13.

Original reporting
SEC EDGAR · Gengos Andrew
Published Nov 16, 2026, 9:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 11:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IMRX
Bullish
medium confidence
Mentioned
$IMRX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IMRXBullishLow
01

Why it matters

The disclosure may slightly improve sentiment among traders tracking insider activity, but it does not change company fundamentals based on the provided text.

02

Market read

Traders may monitor IMRX for follow-on insider activity, but the transaction size and lack of accompanying business updates suggest low immediate trading impact.

03

What to watch

The article provides no context on prior holdings, compensation, or whether the purchase was funded by sales elsewhere; without that, the signal strength is limited.

Relevance 4/10Novelty 6/10Timing: Form 4 filed Nov. 16, 2026, covering a purchase on Nov. 13, 2026.

Background

The filing is an SEC Form 4 insider transaction by Immuneering Corp’s CFO.

Company-level read

Ticker impact

$IMRXBullishMedium confidence
Context

CFO Gengos Andrew bought 25,000 shares of Immuneering Corp at $3.58/share in a Form 4 filed Nov. 16, 2026.

Expected impact

Likely limited near-term impact, with any effect fading unless followed by additional insider buying or fundamental catalysts.

Evidence & confidence

The article is a primary Form 4 insider purchase with modest dollar value and no 10b5-1 plan, which may attract attention but typically does not create a strong, durable price signal alone.

Market effects

Minimal sector read-through; this is a single-company insider transaction without operational or clinical updates.

None.

None.

Counterpoint

Insider purchases can be routine liquidity or diversification activity, and the absence of a 10b5-1 plan does not guarantee a bullish fundamental view.

Key entities

  • Immuneering Corp

    US-listed company (IMRX) whose CFO filed an insider purchase Form 4.

  • Gengos Andrew

    CFO who purchased 25,000 shares at $3.58/share on Nov. 13, 2026.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IMRXHigh

Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates

Immuneering Corp (IMRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates - Phase 2 pancreatic cancer follow-up extended as patients on atebimetinib combinations live longer than projected - - Updated Phase 2 atebimetinib + mGnP pancreatic cancer data (N

$IMRXMed

Immuneering presents phase 3 pancreatic cancer trial design

Immuneering Corporation (IMRX) presented its Phase 3 trial design for atebimetinib in pancreatic cancer at the European Society for Medical Oncology Congress. The global study compares atebimetinib with modified chemotherapy against standard treatment, with overall survival as the primary endpoint. The trial follows promising Phase 2a results and is currently recruiting patients.